Patents by Inventor Ivan J. Fuss

Ivan J. Fuss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment or prevention of an intestinal disease or disorder
    Patent number: 10058559
    Abstract: Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: August 28, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Warren Strober, Ivan J. Fuss, Tetsuya Takagawa, Atsushi Kitani
  • TREATMENT OR PREVENTION OF AN INTESTINAL DISEASE OR DISORDER
    Publication number: 20170079987
    Abstract: Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.
    Type: Application
    Filed: May 15, 2015
    Publication date: March 23, 2017
    Inventors: Warren Strober, Ivan J. Fuss, Tetsuya Takagawa, Atsushi Kitani
  • Methods of treating and preventing colitis involving IL-13 and NK-T cells
    Patent number: 8821866
    Abstract: Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: September 2, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Warren Strober, Ivan J. Fuss, Frank Heller, Richard S. Blumberg
  • METHODS OF TREATING AND PREVENTING COLITIS INVOLVING IL-13 AND NK-T CELLS
    Publication number: 20120276113
    Abstract: Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.
    Type: Application
    Filed: May 4, 2012
    Publication date: November 1, 2012
    Applicant: The Government of the United States of America, as represented by the Secretary, Department of Healt
    Inventors: Warren Strober, Ivan J. Fuss, Frank Heller, Richard S. Blumberg
  • Methods of treating colitis involving IL-13 and NK-T cells
    Patent number: 8173123
    Abstract: Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: May 8, 2012
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Brigham & Women's Hospital
    Inventors: Warren Strober, Ivan J. Fuss, Frank Heller, Richard Blumberg
  • TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-ALPHA2
    Publication number: 20110268749
    Abstract: Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13R?2 antagonist, and/or a AP-I antagonist.
    Type: Application
    Filed: July 31, 2008
    Publication date: November 3, 2011
    Applicant: The Government of the US as Represented by the Secretary Department of Health and Human Services
    Inventors: Warren Strober, Jay A. Berzofsky, Stefan Fichtner-Feigl, Atsushi Kitani, Ivan J. Fuss, Masaki Terabe, Peter Mannon
  • METHODS OF TREATING AND PREVENTING COLITIS INVOLVING IL-13 AND NK-T CELLS
    Publication number: 20100143339
    Abstract: Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.
    Type: Application
    Filed: February 19, 2010
    Publication date: June 10, 2010
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Service
    Inventors: Warren Strober, Ivan J. Fuss, Frank Heller, Richard S. Blumberg
  • Methods of treating and preventing colitis involving IL-13 and NK-T cells
    Patent number: 7666411
    Abstract: Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: February 23, 2010
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Brigham & Women's Hospital, Inc.
    Inventors: Warren Strober, Ivan J. Fuss, Frank Heller, Richard S. Blumberg
  • Inducible plasmid vector encoding TGF-? and use thereof
    Patent number: 7531352
    Abstract: The present invention provides alternatives to traditional drug and surgical treatments for IBD. In particular, the present invention provides compositions and methods for the treatment of autoimmune diseases such as IBD in humans using TGF-? therapy. The compositions of the present invention provide vectors containing TGF-? under the control of an inducible promoter. In particularly preferred embodiments, the present invention provides regulated plasmid constructs capable of inducing TGF-? production. In preferred embodiments, the methods of the present invention utilize the vectors described for assaying the expression of a gene in a cell. In some preferred embodiments, the methods of the present invention utilize the administration of TGF-? containing vectors to treat IBD. In alternative preferred embodiments, the present invention provides methods and compositions for the induction of high-level interleukin (e.g., IL-10) production.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: May 12, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Warren Strober, Kazuhiko Nakamura, Atsushi Kitani, Ivan J. Fuss, Jr.
  • Methods of treating inflammatory bowel disease using cholera toxin B subunit
    Patent number: 7041296
    Abstract: The present invention provides a method of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. The present invention also provides a method of decreasing the activity of interferon gamma in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Further provided is a method of decreasing the activity of IL-12 in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Additionally, the present invention provides a method of treating or preventing a Th1 T-cell mediated autoimmune disorder in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: May 9, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Warren Stober, Ivan J. Fuss, Brian L. Kelsall, Monica Boirivant